
A New; Rapidly Dissolving And Thermally Stable Dry Powder Hepatitis-B VaccineAward last edited on: 7/26/13
Sponsored Program
SBIRAwarding Agency
NIH : NIAIDTotal Award Amount
$1,139,918Award Phase
2Solicitation Topic Code
-----Principal Investigator
Stephen P CapeCompany Information
Phase I
Contract Number: 1R43AI089149-01Start Date: 4/5/10 Completed: 3/31/11
Phase I year
2010Phase I Amount
$200,000Public Health Relevance:
This project seeks to accelerate Immunoject, a new unit-dose, auto-reconstitution device for parenteral delivery, on its path to commercialization. The new device will significantly reduce the costs of storing and administering a prophylactic or therapeutic dose to subjects of a mass public health campaign provoked by the transmission of a bioterrorist or naturally occurring pathogen. Key to Immunoject's potential is the innovative formulation of active ingredients as thermally stable and rapidly dissolving dry powders.
Thesaurus Terms:
Atgn; Adjuvant; Alum Adjuvant; Antigens; Assay; Australia Antigen; Bioassay; Biologic Assays; Biological Assay; Devices; Dose; Drug Formulations; Equilibrium; Excipients; Film; Formulation; Formulations, Drug; Fungi, Filamentous; Goals; Hbv Vaccine; Hbsag; Hbsag (Hepatitis B Surface Antigen); Health Campaign; Health Care Providers; Health Personnel; Healthcare Providers; Healthcare Worker; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B Virus Vaccine; Hour; Housing; Hydrogen Oxide; Injection Of Therapeutic Agent; Injections; Membrane; Mercurate(1-), Ethyl(2-Mercaptobenzoato(2-)-O,S)-, Sodium; Mercurothiolate; Molds; Needles; Patients; Performance; Permeability; Pharmaceutical Agent; Pharmaceuticals; Pharmacologic Substance; Pharmacological Substance; Plastics; Powder Dose Form; Powders; Pressure; Pressure- Physical Agent; Process; Public Health; Rewards; Risk; System; System, Loinc Axis 4; Technology; Temperature; Testing; Therapeutic; Thimerosal; Thiomersal; Thiomersalate; Thumb; Thumb Structure; Time; Transmission; Vaccines; Water; Alum; Aluminum Sulfate; Balance; Balance Function; Commercialization; Communicable Disease Transmission; Cost; Disease Transmission; Health Care Personnel; Health Care Worker; Health Provider; Healthcare Personnel; Hepatitis Associated Antigen; Immunogen; Infectious Disease Transmission; Innovate; Innovation; Innovative; Medical Personnel; Membrane Structure; Microbial; Nano; Pathogen; Pressure; Prophylactic; Public Health Medicine (Field); Public Health Relevance; Reconstitute; Reconstitution; Seal; Success; Therapeutic Vaccine; Transmission Process; Treatment Provider; User-Friendl
Phase II
Contract Number: 2R44AI089149-02Start Date: 00/00/00 Completed: 00/00/00
Phase II year
2012(last award dollars: 2013)
Phase II Amount
$939,918Public Health Relevance:
This project seeks to accelerate a new Hepatitis-B vaccine formulation on its path to commercialization. A commercially available thimerosal-free liquid vaccine, Shanvac-B, was formulated as a dry, rapidly dissolving micro-powder with stability over an 18-month period at temperatures ranging from -20 oC through 65 oC. When considered in the context of combining Aktiv-Dry's vaccine powders with single dose auto-reconstitution devices, these results have far-reaching implications in regard to vaccine storage, transport and administration, especially in developing countries where limited refrigeration and electric power and high ambient temperatures restrict the useful life and potency of liquid vaccines.